On August 14, 2025, Tyra Biosciences reported its financial results for the second quarter ended June 30, 2025. The company announced cash, cash equivalents, and marketable securities totaling $296.3 million as of June 30, 2025, maintaining a projected cash runway through at least 2027.
The net loss for the second quarter of 2025 was $28.098 million, an increase from the $18.702 million net loss reported for the same period in 2024. For the six months ended June 30, 2025, the net loss was $56.245 million, compared to $36.894 million for the corresponding period in 2024.
Research and development expenses for Q2 2025 were $24.309 million, up from $17.997 million year-over-year, reflecting continued investment in clinical programs. General and administrative expenses also increased to $7.143 million from $5.535 million. The company highlighted the dosing of the first patient in the SURF302 study for intermediate risk non-muscle invasive bladder cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.